Promising drug trial for kids with rare Muscle-Weakening disease

NCT ID NCT05644561

Ongoing Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called ravulizumab in 12 children aged 6 to 18 with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The goal is to see how the drug works in the body and if it helps control symptoms. Participants receive the drug through an IV, and the study focuses on safety and effectiveness over 18 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS GMG

Contacts and locations

Locations

Research Site

Los Angeles, California, 90078, United States
Research Site

Boston, Massachusetts, 02115, United States
Research Site

Chapel Hill, North Carolina, 27514, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Milan, 20133, Italy
Research Site

Roma, 00165, Italy
Research Site

Torino, 10126, Italy
Research Site

Itabashi-ku, 173-0003, Japan
Research Site

Belgrade, 11000, Serbia
Research Site

Belgrade, 11070, Serbia
Research Site

Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.